Showing 1201-1210 of 4012 results for "".
10 Mistakes by Device Brands Entering New Markets
https://reachmd.com/topics/energy-based-devices/10-mistakes-by-device-brands-entering-new-markets/39731/Critical insights for practitioners when choosing industry partnersClemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
https://reachmd.com/programs/neurofrontiers/clemastine-fumarate-and-progressive-ms-a-closer-look-at-unexpected-risks-and-mechanisms/32825/The Next Big Thing
https://reachmd.com/topics/practice-development/the-next-big-thing/35174/Will Nextdoor become the next big social network?Reframing Palliative Care in PAH: Early Integration to Improve Outcomes
https://reachmd.com/programs/clinicians-roundtable/reframing-palliative-care-in-pah-early-integration-to-improve-outcomes/56326/Silent Threats in a Pandemic: The Emotional Tolls of Self-Isolation
https://reachmd.com/programs/covid-19-frontlines/silent-threats-pandemic-emotional-tolls-self-isolation/11344/Clinicians at high risk of exposure from COVID-19 are facing difficult choices about how to keep their loved ones safe.Aesthetic Laser Innovators Discuss What Is Next
https://reachmd.com/programs/modern-aesthetics-focus-on-energy-based-devices/aesthetic-laser-innovators-discuss-what-is-next/56627/A roundtable discussion with Jill S. Waibel, MD, FACS, FAAD; R. Rox Anderson, MD, FAAD; Roy Geronemus, MD; and E. Victor Ross, MD, FAADDisease-Modifying Advances in ATTR-CM Management
https://reachmd.com/programs/heart-matters/disease-modifying-attr-cm-management/49063/Calming Overactive Immune Response and Reducing Inflammation with TYK2 Inhibition in Psoriasis
https://reachmd.com/programs/cme/calming-overactive-immune-response-and-reducing-inflammation-with-tyk2-inhibition-in-psoriasis/50978/Join us to learn about the emerging data with TKY2 inhibitors for treatment of psoriasis.IBD Masterclass: Foundations of Pathophysiology and Targeted Therapy
https://reachmd.com/programs/cme/ibd-masterclass-foundations-of-pathophysiology-and-targeted-therapy/49149/Examine the biological mechanisms underlying IBD, including genetic, microbial, environmental, and immune pathways that inform therapeutic targets.The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
https://reachmd.com/programs/cme/the-new-era-of-ras-targeting-mechanisms-evidence-and-clinical-integration-of-on-state-inhibitors/39770/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.